Matrix metalloproteinases in metabolic syndrome

Area of Science:

• Cardiovascular biology
• Molecular medicine
• Pathophysiology of metabolic syndrome

Background:

• Metabolic syndrome is linked to increased cardiovascular risk, endothelial dysfunction, and vascular complications.
• Pathogenesis involves endothelial basal membrane remodeling, leukocyte activation, oxidative stress, and altered matrix metalloproteinases (MMPs) expression.
• MMPs degrade extracellular matrix; their dysregulation by tissue inhibitors of MMP (TIMPs) is implicated in atherosclerotic plaque instability and mortality.

Purpose of the Study:

• To investigate the role of matrix metalloproteinases (MMPs) and tissue inhibitors of MMP (TIMPs) in metabolic syndrome.
• To explore the link between MMP/TIMP dysregulation and cardiovascular complications in metabolic syndrome.
• To highlight the potential of targeting MMP/TIMP pathways for therapeutic intervention.

Main Methods:

• Review of existing literature on MMPs, TIMPs, and metabolic syndrome.
• Analysis of studies evaluating MMP/TIMP patterns in components of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia).
• Examination of evidence linking MMP/TIMP alterations to cardiovascular events and mortality.

Main Results:

• Altered MMP and TIMP expression is a common feature in conditions defining metabolic syndrome.
• MMP/TIMP dysregulation contributes to endothelial dysfunction and atherosclerotic plaque instability.
• Impaired MMP or TIMP expression is associated with increased all-cause mortality risk.

Conclusions:

• Matrix metalloproteinases (MMPs) and tissue inhibitors of MMP (TIMPs) play a significant role in the vascular pathology of metabolic syndrome.
• Further research into MMP/TIMP modulation is warranted to develop strategies against atherosclerosis.
• Therapeutic strategies targeting the MMP/TIMP balance may reduce cardiovascular morbidity and mortality in metabolic syndrome patients.